Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00024-5151-75 00024-5151 Rasburicase Elitek Ancillary Therapy Metabolic Agent Enzyme June 1, 2006 In Use
62935-0452-45 62935-0452 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Jan. 23, 2002 April 26, 2019 No Longer Used
62935-0222-05 62935-0222 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Aug. 26, 2002 April 26, 2019 In Use
62935-0302-30 62935-0302 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Feb. 26, 2003 April 26, 2019 In Use
62935-0752-75 62935-0752 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous May 15, 2002 April 26, 2019 In Use
62935-0303-30 62935-0303 Leuprolide Acetate Eligard Hormonal Therapy GnRH Agonist Subcutaneous Feb. 26, 2003 In Use
62935-0461-50 62935-0461 Leuprolide acetate Eligard 45.0 mg/.375mL Hormonal Therapy GnRH Agonist Subcutaneous March 6, 2023 In Use
62935-0227-10 62935-0227 Leuprolide acetate Eligard 22.5 mg/.375mL Hormonal Therapy GnRH Agonist Subcutaneous Nov. 27, 2023 In Use
62935-0306-40 62935-0306 Leuprolide acetate Eligard 30.0 mg/.5mL Hormonal Therapy GnRH Agonist Subcutaneous Jan. 11, 2024 In Use
62935-0756-80 62935-0756 Leuprolide acetate Eligard 7.5 mg/.25mL Hormonal Therapy GnRH Agonist Subcutaneous Nov. 1, 2023 In Use

Found 10,000 results in 8 milliseconds — Export these results